Retroviral DNMT3L Vector for DNMT3A Deficiency Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for DNMT3A deficiency-associated diseases, such as leukemia and acute myeloid leukemia, are limited in effectively addressing loss-of-function mutations and dominant negative mutations that lead to DNA hypomethylation and abnormal myeloid skewing.

Innovation Solution

The method involves administering a retroviral vector containing DNMT3L cDNA to increase DNMT3A activity, combined with therapeutic agents like HDAC inhibitors and hypomethylating agents, to reactivate DNMT3L expression and restore methylation in bone marrow cells, thereby promoting cancer cell death and correcting abnormal myeloid skewing.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments are used for DNMT3A deficiency-associated diseases, then general cancer therapy is provided, but the treatments are ineffective against loss-of-function and dominant negative mutations causing DNA hypomethylation

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidmutation type coverage

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the therapeutic parameter from general chemotherapy to targeted epigenetic modulation by using HDAC inhibitors and hypomethylating agents that specifically address the DNA hypomethylation caused by DNMT3A mutations, thereby improving treatment effectiveness for this specific mutation type

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces DNMT3L as an intermediary protein that can compensate for the loss of DNMT3A function. By administering DNMT3L or vectors expressing DNMT3L, the treatment mediates the restoration of de novo methylation capacity in cells with DNMT3A loss-of-function or dominant negative mutations

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If DNMT3L expression is reactivated to restore DNMT3A activity, then DNA methylation is restored in bone marrow cells, but the complexity of the treatment approach increases

Engineering Contradiction:

ImproveDNA methylation restorationVSAvoidtreatment protocol complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses retroviral vectors to deliver DNMT3L cDNA into bone marrow cells before the disease progresses, establishing a preliminary genetic modification that enables sustained DNMT3L expression and continuous restoration of DNA methylation, thereby simplifying long-term treatment compared to repeated pharmacological interventions

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent replaces the mechanical/pharmacological approach of continuously administering drugs with a biological/genetic approach where the retroviral vector establishes self-sustaining DNMT3L expression, substituting complex drug delivery systems with a self-regulating genetic system

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If retroviral vectors are used to deliver DNMT3L cDNA, then DNMT3L expression is increased in bone marrow cells, but the risk of viral integration and off-target effects increases

Engineering Contradiction:

ImproveDNMT3L expression increaseVSAvoidviral integration risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by targeting the retroviral vector specifically to bone marrow cells, the site of DNMT3A deficiency and disease origin. By concentrating the therapeutic effect in the specific tissue affected by the mutation, the treatment maximizes benefit while limiting viral integration risks to a specific cell population rather than the entire organism

Inventive Principle:

Principle #3Local quality

4Reliability

If HDAC inhibitors and hypomethylating agents are administered to reactivate DNMT3L, then DNMT3A enzymatic activity is increased, but the side effects of these therapeutic agents increase

Engineering Contradiction:

ImproveDNMT3A enzymatic activityVSAvoidtherapeutic agent side effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent uses HDAC inhibitors and hypomethylating agents as preliminary actions to create a permissive epigenetic environment that reactivates DNMT3L expression. This preliminary epigenetic modulation is followed by or combined with retroviral delivery of DNMT3L, allowing the drugs to be used at lower doses and for shorter durations, thereby reducing their harmful side effects while still achieving the desired enzymatic activity

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20240384244A1Methods and compositions for treating DNMT3a deficiency-associated diseases

Publication Date: 2024.11.21 WASHINGTON UNIV IN SAINT LOUIS

AI summary

Treatment and prevention of DNMT3A deficiency-associated diseases are provided. Compositions for treatment or prevention include at least one cDNA vector and/or at least one therapeutic agent capable of restoring DNMT3L activity, restoring DNMT3L expression, increasing DNMT3L activity, increasing DNMT3L expression, and/or increasing DNMT3A enzymatic activity. Methods for treatment or prevention include administering to a subject a composition including the at least one cDNA vector and/or at least one therapeutic agent. Methods of increasing DNMT3A activity in a subject having a DNMT3A mutation, methods of reversing a hypomethylation phenotype in bone marrow cells of a subject having a DNMT3A mutation, and methods of promoting cancer cell death in a subject having Acute Myeloid Leukemia (AML) are also provided.